Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer
| Autor: | Kiyoshi Takahara, Haruhito Azuma, Hayahito Nomi, Yoji Katsuoka, Kazumasa Komura, Kazuhiro Yamamoto, Teruo Inamoto, Yatsugu Kotake, Satoshi Kiyama, Yoshihumi Narumi, Naokazu Ibuki, Hiroshi Uehara, Takanobu Ubai |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Urinary system Urology Cystectomy Deoxycytidine Disease-Free Survival Catheterization Risk Factors Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intra-Arterial Aged Neoplasm Staging Aged 80 and over Bladder cancer Urinary bladder business.industry Cancer medicine.disease Combined Modality Therapy Survival Analysis Gemcitabine Surgery Radiation therapy Regimen Treatment Outcome medicine.anatomical_structure Urinary Bladder Neoplasms Oncology Female Cisplatin business medicine.drug |
| Zdroj: | International Journal of Oncology. 38 |
| ISSN: | 1791-2423 1019-6439 |
| Popis: | In this study, we investigated the novel bladder preservation therapy, the balloon-occluded arterial infusion (BOAI) of cisplatin/gemcitabine, concomitantly with hemodialysis, along with concurrent irradiation [the 'Osaka Medical College (OMC)-regimen'] in patients >70 years of age with muscle-invasive bladder cancer. Eighty-three such patients were assigned to receive either the OMC-regimen (n=56) or cystectomy (n=27). The OMC-regimen patients who failed to achieve complete response (CR) underwent cystectomy, or secondary BOAI with gemcitabine (1600 mg). The OMC-regimen, which delivers an extremely high concentration of anti-cancer agent to the tumor site without systemic adverse effects, yielded CR in >90% (39/43) of patients with locally invasive tumors [70% (39/56) of all patients including those with T4 and N+ disease]. None of the CR patients showed recurrence after a mean follow-up of 162 (range, 35-683) weeks, and 2 patients died of unrelated causes. The 5- and 12-year overall survival rates were 92.7 and 69.5% (vs. 59.6 and 20.9% for cystectomy; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|